Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Robert L. Stoll

Advertisement

Articles by Robert L. Stoll

Attacks on Pharmaceutical Improvement Patents

ByRobert L. Stoll,Nick Colic
August 21st 2019

Pharmaceutical Executive

Is Congress harming pharmaceutical research by limiting enforcement of improvement patents?

Advertisement

Latest Updated Articles

  • Attacks on Pharmaceutical Improvement Patents
    Attacks on Pharmaceutical Improvement Patents

    August 21st 2019



Advertisement
Advertisement

Trending on PharmExec

1

Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables

2

Beyond the Molecule: The New Competitive Battlefield in Oncology

3

FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax

4

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

5

Being an Expert Is About More Than Just Knowing the Answers

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us